Kepler Capital Maintains a Hold Rating on GSK plc (GSK)

GSK plc (NYSE:GSK) is one of the best growth stocks under $50 to buy now. In a report released on September 4, David Evans from Kepler Capital maintained a Hold rating on GSK plc (NYSE:GSK), setting a price target of p1,500.00.

GSK plc (NYSE:GSK) released its fiscal Q2 2025 earnings on July 30, reporting total sales of £8.0 billion. Total operating profit for the quarter rose 33% while total EPS increased by 35%, driven by lower CCL charges.

GSK plc (NYSE:GSK) also reported £2.4 billion in cash generated from operations, with free cash flow of £1.1 billion.

Formerly known as GlaxoSmithKline, GSK plc (NYSE:GSK) is a global healthcare and biopharmaceutical corporation that develops and distributes a range of vaccines, medications, and consumer health items. It is based in the United Kingdom and has over 20 vaccines in its portfolio, positioning it as a leader in vaccines, immunology, and respiratory therapies. The company also develops cancer treatments for multiple myeloma, ovarian cancer, and endometrial cancer in addition to other drugs.

While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.